 Connection
Marcy Yonker to Migraine Disorders
This is a "connection" page, showing publications Marcy Yonker has written about Migraine Disorders.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.865 |
|
|
|
-
Yonker ME, McVige J, Zeitlin L, Visser H. A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11?years, with an open-label extension. Headache. 2022 10; 62(9):1207-1217.
Score: 0.659
-
Troy E, Yonker M. ED and Inpatient Management of Headache in Children and Adolescents. Curr Neurol Neurosci Rep. 2020 05 14; 20(6):15.
Score: 0.559
-
Hickman C, Lewis KS, Little R, Rastogi RG, Yonker M. Prevention for Pediatric and Adolescent Migraine. Headache. 2015 Nov-Dec; 55(10):1371-81.
Score: 0.406
-
Yonker M, Mangum T. Migraine management in children. Curr Neurol Neurosci Rep. 2015 May; 15(5):20.
Score: 0.394
-
Yonker ME. Pharmacologic treatment of migraine. Curr Pain Headache Rep. 2006 Oct; 10(5):377-81.
Score: 0.217
-
Clementi MA, Kienzler C, Yonker M, Harmon M, Simon SL. Preliminary exploration of a multidimensional sleep health composite in adolescent females with frequent migraine. Headache. 2023 Nov-Dec; 63(10):1437-1447.
Score: 0.176
-
Ackley E, Asamoah P, Mirsky D, White C, Maloney J, Stence N, Silveira L, Yonker M, Neuberger I. Dots and spots: A retrospective review of T2-hyperintense white matter lesions in pediatric patients with and without headache. Headache. 2023 05; 63(5):611-620.
Score: 0.171
-
Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. Headache. 2020 03; 60(3):564-575.
Score: 0.137
-
Turner SB, Rende EK, Pezzuto T, Weaver S, Henderlong-Kropp A, Greene KA, Bicknese AR, Dilts JJ, Gautreaux J, Victorio MCC, Strauss LD, Lagman-Bartolome AM, Szperka CL, Yonker M, Hershey AD, Gelfand AA. Pediatric Migraine Action Plan (PedMAP). Headache. 2019 11; 59(10):1871-1873.
Score: 0.135
-
Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, Holler-Managan Y, Leininger E, Licking N, Mack K, Powers SW, Sowell M, Cristina Victorio M, Yonker M, Zanitsch H, Hershey AD. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Headache. 2019 09; 59(8):1144-1157.
Score: 0.133
-
Hershey AD, Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Licking N, Sowell M, Victorio MC, Gersz E, Vrijsen E, Zanitsch H, Yonker M, Mack K, Gelfand AA, Szperka CL, Powers SW. New Guidelines: Interpretation, Application and the Future. Headache. 2019 09; 59(8):1133-1143.
Score: 0.133
-
Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Hershey AD, Licking N, Sowell M, Victorio MC, Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Headache. 2019 09; 59(8):1158-1173.
Score: 0.133
-
Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, Holler-Managan Y, Leininger E, Licking N, Mack K, Powers SW, Sowell M, Victorio MC, Yonker M, Zanitsch H, Hershey AD. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019 09 10; 93(11):500-509.
Score: 0.133
-
Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Hershey AD, Licking N, Sowell M, Victorio MC, Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019 09 10; 93(11):487-499.
Score: 0.133
-
Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. Headache. 2018 11; 58(10):1658-1669.
Score: 0.125
-
Leung S, Bulloch B, Young C, Yonker M, Hostetler M. Effectiveness of standardized combination therapy for migraine treatment in the pediatric emergency department. Headache. 2013 Mar; 53(3):491-197.
Score: 0.085
-
Hershey AD, Winner P, Kabbouche MA, Gladstein J, Yonker M, Lewis D, Pearlman E, Linder SL, Rothner AD, Powers SW. Use of the ICHD-II criteria in the diagnosis of pediatric migraine. Headache. 2005 Nov-Dec; 45(10):1288-97.
Score: 0.051
-
Lewis DW, Yonker M, Winner P, Sowell M. The treatment of pediatric migraine. Pediatr Ann. 2005 Jun; 34(6):448-60.
Score: 0.050
-
Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B, Irwin SL. Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents. Pediatr Neurol. 2021 01; 114:62-67.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|